Metformin (500mg) + Voglibose (0.3mg)
Vogipax M 0.3 Tablet SR is used in the treatment of type 2 diabetes.
1 Strip of 10 Tablet
Image shown is a representation and may slightly vary from the actual product. Every effort is made to maintain accuracy of all information displayed.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Vogipax M 0.3 Tablet SR is to be taken with food.
Vogipax M 0.3 Tablet SR may cause stomach upset if taken on empty stomach.
Vogipax M 0.3 Tablet SR is a combination of two antidiabetic medicines: Metformin and voglibose. Metformin lowers the production and absorption of sugar in your body and allows better use of existing insulin. Voglibose inhibits the intestinal enzymes that cause breakdown of complex sugars into simple sugars such as glucose. This prevents blood glucose from rising very high after meals.
Related Warnings
Taking Voglibose with alcohol reduce the blood sugar levels in diabetic patients.
Vogipax M 0.3 Tablet SR is probably safe to use during pregnancy.
Animal studies have shown low or no adverse effect on the foetus, however, there are limited human studies. Please consult your doctor.
Vogipax M 0.3 Tablet SR is probably safe to use during lactation. Limited human data suggests that the drug does not represent a significant risk to the baby.
Your ability to drive may be affected if your blood sugar is low or high. If this happens, do not drive.
Vogipax M 0.3 Tablet SR should be used with caution in patients with kidney disease. Dose adjustment of Vogipax M 0.3 Tablet SR may be needed. Please consult your doctor.
Use of Vogipax M 0.3 Tablet SR is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Vogipax M 0.3 Tablet SR should be used with caution in patients with liver disease. Dose adjustment of Vogipax M 0.3 Tablet SR may be needed. Please consult your doctor.
Vogipax M 0.3 Tablet SR is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.
